Haleon Pakistan Limited has started manufacturing Panadol 500mg tablets at its own facility in Jamshoro, Sindh, marking an important development for the country’s pharmaceutical industry.
The company announced the commencement of production in a notice submitted to the Pakistan Stock Exchange (PSX) on October 30, 2026. The move aims to strengthen local manufacturing capabilities and support the reliable availability of the popular pain relief medicine.
The development follows an investment of approximately $10 million, announced in October 2023, to introduce modern manufacturing technology and increase production capacity at the Jamshoro facility.
Haleon Pakistan also announced a change in the appearance of the locally manufactured tablets. The new Panadol 500mg tablets will feature a beacon engraving instead of the existing “Panadol” lettering.
According to the company, the change is limited to the tablet’s design, while its quality and effectiveness remain unchanged.
The company described the start of production as a significant milestone in strengthening its in-house manufacturing operations and improving its ability to supply products to consumers across Pakistan.
Local manufacturing can help pharmaceutical companies manage production and supply chains more directly. However, actual improvements in medicine availability will depend on production levels, the availability of raw materials and distribution arrangements.
Haleon Pakistan has also invested in expanding its manufacturing and packaging operations. In January 2026, the company approved an investment of approximately £3.58 million to upgrade its Panadol liquid packaging line, covering products including Children’s Panadol Drops and Children’s Panadol Liquid.
The latest development highlights continued investment in Pakistan’s consumer healthcare sector. Increased domestic manufacturing capacity may support industrial activity, technical expertise and employment opportunities.
